Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
Specific transaction details include:
- Transaction Date: January 12, 2010
- Transaction Type: Increase in notional interests following the re-investment of dividends paid on January 7, 2010.
- Share Price: £12.94 per Ordinary share; $41.48 per Ordinary Share ADR.
Material Changes
The filing reports an increase in notional share interests for various executives. No material changes to the company's financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that notional dividends accrued will be paid out based on the percentage of holdings that vest after the relevant three-year measurement period.
Important Facts for Investors to Verify
- Verify the vesting schedule and conditions for the Performance Share Plan to understand when notional dividends become payable.
- Confirm the total number of shares and ADRs held by the listed directors prior to this transaction to assess total exposure.
- Review the dividend payment date of January 7, 2010, to ensure alignment with the company's broader dividend policy.